SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Silsbee who wrote (2365)10/17/1997 9:24:00 AM
From: Biomaven   of 6136
 
Peter,

>>>as time goes on, the first population will make up a greater and greater proportion of the total, so any PI which has been widely used will become less and less effective in supposedly PI-naive patients.>>>

This assumes the mutated strains are as transmissable as the wild type, something I don't think anyone knows. Also, at least in the US, the dominant population for Viracept is by far those patients who are already infected today (and perhaps are not yet diagnosed) rather than brand new infections.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News